Author Archives: Joana Carvalho

Repeated Doses of Rituximab May Improve AAV Patients’ Response to the Medication, Study Suggests

Administering rituximab repeatedly may improve the response of patients with ANCA-associated vasculitis (AAV) to the medication, a study says. The findings were reported in the study, “Non‐Linear Rituximab Pharmacokinetics and Complex Relationship between Rituximab Concentrations and Anti‐Neutrophil Cytoplasmic Antibodies (ANCA) in ANCA‐Associated Vasculitis: The RAVE Trial Revisited,”…

Intravenous Immunoglobulin Quickly Lowers Disease Activity in AAV Patients, Review Study Finds

Intravenous immunoglobulin (IVIG) therapy leads to a fast and significant reduction in disease activity, as well as in the levels of inflammatory biomarkers, in people with ANCA-associated vasculitis (AAV), a review of several studies found. The study, “The therapeutic efficacy of intravenous immunoglobulin in anti-neutrophilic cytoplasmic antibody-associated…

Antimicrobial Traps in AAV Patients Differ From Those With SLE, Study Says

The formation, composition, and structure of antimicrobial traps in ANCA-associated vasculitis (AAV) patients are markedly different from those with systemic lupus erythematosus (SLE), a study says. The findings of the study, “Neutrophil extracellular trap formation is intrinsically distinct in ANCA‐associated vasculitis and systemic lupus erythematosus,” were published…

Anti-NET Antibodies May Prevent Normal Degradation of Antimicrobial Traps in MPA Patients, Study Says

Some patients with microscopic polyangiitis (MPA) produce antibodies against antimicrobial traps that may partly explain why these traps are capable of withstanding normal degradation, a study says. The study, “The presence of anti-neutrophil extracellular trap antibody in patients with microscopic polyangiitis,” was published in the journal Rheumatology.